Should Drug Makers Be Required to Take FDA Advice on Pivotal Trials?

The Wall Street Journal - Quotes Steven Woloshin and Lisa Schwartz, professors of medicine, who argue that clinical trial designs could be enhanced and, therefore, study results may be bolstered if drug makers were mandated to submit all study protocols to the Food and Drug Administration for review. Read more...